LAVA TherapeuticsLVTX
LVTX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
10.9% more ownership
Funds ownership: 13.73% [Q3] → 24.62% (+10.9%) [Q4]
5% more funds holding
Funds holding: 21 [Q3] → 22 (+1) [Q4]
3% more capital invested
Capital invested by funds: $5.99M [Q3] → $6.15M (+$164K) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1.50
29%
upside
Avg. target
$1.50
29%
upside
High target
$1.50
29%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Arthur He 12% 1-year accuracy 4 / 33 met price target | 29%upside $1.50 | Neutral Reiterated | 31 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2024.

Negative
Benzinga
1 month ago
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
On Tuesday, LAVA Therapeutics N.V. LVTX initiated a process to review strategic options.

Neutral
GlobeNewsWire
2 months ago
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Neutral
GlobeNewsWire
3 months ago
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, reported financial results for the third quarter ended September 30, 2024 and announced a strategic pipeline reprioritization.

Neutral
GlobeNewsWire
7 months ago
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference.

Neutral
GlobeNewsWire
7 months ago
LAVA Reports Second Quarter 2024 Financial Results and Business Update
UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate highlights.

Positive
24/7 Wall Street
7 months ago
4 Stocks Under $5 To Buy Now
Are you looking for stocks to buy with low price tags?

Positive
Zacks Investment Research
8 months ago
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
LAVA Therapeutics (LVTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Neutral
GlobeNewsWire
9 months ago
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.

Neutral
GlobeNewsWire
9 months ago
LAVA Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST.

Charts implemented using Lightweight Charts™